BR0112734A - Agente terapêutico cristalino - Google Patents

Agente terapêutico cristalino

Info

Publication number
BR0112734A
BR0112734A BR0112734-9A BR0112734A BR0112734A BR 0112734 A BR0112734 A BR 0112734A BR 0112734 A BR0112734 A BR 0112734A BR 0112734 A BR0112734 A BR 0112734A
Authority
BR
Brazil
Prior art keywords
therapeutic agent
crystalline therapeutic
crystalline
pyridylsulfonyl
ethylpiperazine
Prior art date
Application number
BR0112734-9A
Other languages
English (en)
Inventor
Laurence James Harris
Richard Anthony Storey
Albert Shaw Wood
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0018656A external-priority patent/GB0018656D0/en
Priority claimed from GB0106464A external-priority patent/GB0106464D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of BR0112734A publication Critical patent/BR0112734A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

"AGENTE TERAPêUTICO CRISTALINO". A presente invenção refere-se a um polimorfo de 1-{6-etóxi-5-[3-etil-6,7-dihidro-2-(2-metoxietil)-7-oxo-2H-pirazolo[4,3-d ]-pirimidin-5-il]-3-piri-dilsulfonil}-4-etilpiperazina.
BR0112734-9A 2000-07-28 2001-07-18 Agente terapêutico cristalino BR0112734A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0018656A GB0018656D0 (en) 2000-07-28 2000-07-28 Pharmaceutically active compounds
GB0106464A GB0106464D0 (en) 2001-03-15 2001-03-15 Crystalline therapeutic agent
PCT/IB2001/001280 WO2002010171A1 (en) 2000-07-28 2001-07-18 Crystalline therapeutic agent

Publications (1)

Publication Number Publication Date
BR0112734A true BR0112734A (pt) 2004-08-10

Family

ID=26244756

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0112734-9A BR0112734A (pt) 2000-07-28 2001-07-18 Agente terapêutico cristalino

Country Status (46)

Country Link
EP (1) EP1305314B1 (pt)
JP (1) JP2004505087A (pt)
KR (1) KR100457937B1 (pt)
CN (1) CN1207297C (pt)
AP (1) AP1400A (pt)
AR (1) AR032628A1 (pt)
AT (1) ATE286901T1 (pt)
AU (2) AU7269001A (pt)
BG (1) BG107266A (pt)
BR (1) BR0112734A (pt)
CA (1) CA2417264C (pt)
CZ (1) CZ2003126A3 (pt)
DE (1) DE60108398T2 (pt)
DO (1) DOP2001000217A (pt)
DZ (1) DZ3364A1 (pt)
EA (1) EA004681B1 (pt)
EC (1) ECSP034454A (pt)
EE (1) EE200300045A (pt)
ES (1) ES2231521T3 (pt)
GE (1) GEP20053494B (pt)
HK (1) HK1055954A1 (pt)
HR (1) HRP20030061A2 (pt)
HU (1) HUP0302982A3 (pt)
IL (1) IL153226A0 (pt)
IN (1) IN2002MU01649A (pt)
IS (1) IS6626A (pt)
MA (1) MA26931A1 (pt)
MX (1) MX233602B (pt)
MY (1) MY117831A (pt)
NO (1) NO324220B1 (pt)
NZ (1) NZ523226A (pt)
OA (1) OA12337A (pt)
PA (1) PA8523501A1 (pt)
PE (1) PE20020277A1 (pt)
PH (1) PH12001001922B1 (pt)
PL (1) PL365133A1 (pt)
PT (1) PT1305314E (pt)
SK (1) SK572003A3 (pt)
SV (1) SV2001000570A (pt)
TN (1) TNSN01112A1 (pt)
TW (1) TWI285643B (pt)
UA (1) UA72631C2 (pt)
UY (1) UY26854A1 (pt)
WO (1) WO2002010171A1 (pt)
YU (1) YU4703A (pt)
ZA (1) ZA200301457B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004072079A1 (en) * 2003-02-11 2004-08-26 Pfizer Limited Hydrated and anhydrous sildenafil hemi-citrate compound
EP1620437B1 (en) 2003-04-29 2009-06-17 Pfizer Limited 5,7-diaminopyrazolo¬4,3-d pyrimidines useful in the traetment of hypertension
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
DK1742950T3 (da) 2004-04-07 2009-03-16 Pfizer Ltd Pyrazolo-[4,3-D]-pyrimidiner
EA012577B1 (ru) 2005-05-12 2009-10-30 Пфайзер Инк. БЕЗВОДНЫЕ КРИСТАЛЛИЧЕСКИЕ ФОРМЫ N-[1-(2-ЭТОКСИЭТИЛ)-5-(N-ЭТИЛ-N-МЕТИЛАМИНО)-7-(4-МЕТИЛПИРИДИН-2-ИЛАМИНО)-1Н-ПИРАЗОЛО[4,3-d]ПИРИМИДИН-3-КАРБОНИЛ]МЕТАНСУЛЬФОНАМИДА

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1073658E (pt) * 1998-04-20 2003-12-31 Pfizer Inibidores de ogmp pdes de pirazolopirimidinona para o tratamento da disfuncao sexual
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them

Also Published As

Publication number Publication date
PA8523501A1 (es) 2002-10-24
AP2001002234A0 (en) 2001-09-30
DZ3364A1 (fr) 2002-02-07
TNSN01112A1 (fr) 2005-11-10
CN1444585A (zh) 2003-09-24
AP1400A (en) 2005-04-28
NZ523226A (en) 2003-07-25
IL153226A0 (en) 2003-07-06
WO2002010171A1 (en) 2002-02-07
MY117831A (en) 2004-08-30
MX233602B (es) 2006-01-10
UA72631C2 (uk) 2005-03-15
BG107266A (bg) 2003-07-31
MXPA03000856A (es) 2003-06-06
GEP20053494B (en) 2005-04-25
UY26854A1 (es) 2002-02-28
JP2004505087A (ja) 2004-02-19
SK572003A3 (en) 2004-05-04
TWI285643B (en) 2007-08-21
AU2001272690B2 (en) 2005-12-08
EP1305314B1 (en) 2005-01-12
EE200300045A (et) 2004-12-15
PE20020277A1 (es) 2002-05-11
DOP2001000217A (es) 2002-10-30
EA200300079A1 (ru) 2003-06-26
HRP20030061A2 (en) 2003-04-30
OA12337A (en) 2006-05-15
PT1305314E (pt) 2005-04-29
CA2417264A1 (en) 2002-02-07
CN1207297C (zh) 2005-06-22
CA2417264C (en) 2007-06-12
PH12001001922B1 (en) 2006-11-21
IN2002MU01649A (pt) 2004-12-11
YU4703A (sh) 2006-01-16
ATE286901T1 (de) 2005-01-15
AR032628A1 (es) 2003-11-19
EA004681B1 (ru) 2004-06-24
NO20030416D0 (no) 2003-01-27
DE60108398D1 (de) 2005-02-17
CZ2003126A3 (cs) 2004-02-18
IS6626A (is) 2002-11-18
NO324220B1 (no) 2007-09-10
AU7269001A (en) 2002-02-13
HUP0302982A2 (hu) 2003-12-29
NO20030416L (no) 2003-02-05
ZA200301457B (en) 2004-04-28
HK1055954A1 (en) 2004-01-30
EP1305314A1 (en) 2003-05-02
HUP0302982A3 (en) 2005-01-28
MA26931A1 (fr) 2004-12-20
ES2231521T3 (es) 2005-05-16
KR100457937B1 (ko) 2004-11-20
ECSP034454A (es) 2003-03-10
SV2001000570A (es) 2002-09-03
DE60108398T2 (de) 2005-12-22
KR20030016430A (ko) 2003-02-26
PL365133A1 (en) 2004-12-27

Similar Documents

Publication Publication Date Title
MXPA03006093A (es) Derivados de n(fenilsulfonil)glicina y su uso terapeutico.
SE9704544D0 (sv) Novel compounds
NO985643L (no) Antimikrobielle blandinger
BR0316375A (pt) Diazinopirimidinas
YU2003A (sh) Stabilne soli o-acetilsalicilne kiseline sa baznim amino-kiselinama
DK0695171T3 (da) Lyosfærer indeholdende gonadotropin
MX9503529A (es) Derivados de glicinamida, procedimiento para su preparacion y medicamentos que los contienen.
CY1105028T1 (el) Υποκατεστημενες c-ιμιδαζο-[1,2-α]πυριδιν-3-υλο-μεθυλαμινες
PT1390371E (pt) Oxazolo- e furopirimidinas e sua utilizacao em medicamentos contra tumores
SE9802208D0 (sv) Novel compounds
CY1105019T1 (el) Υποκατεστημενες c-ιμιδαζο-[1,2-α]πυριδιν-3-υλο-μεθυλαμινες
EA200001010A1 (ru) Применение дексмедетомидина для седативного воздействия в отделении интенсивной терапии
MXPA04001256A (es) Productos de combinacion de derivados de propanolamina aril substituidos con otros ingredientes activos y su uso.
BR0112734A (pt) Agente terapêutico cristalino
EE05241B1 (et) Distamtsiini a-halogenoakrlolderivaadi kasutamine
SE9802209D0 (sv) Novel compounds
WO2002057246A3 (en) Inhibitors of cruzipain and other cysteine proteases
ZA983231B (en) Substituted benzyloxyimino compounds.
CY1105363T1 (el) Ν,ν΄-διυποκατεστημενες ενωσεις πιπepαζινης και η χρηση τους σαν αναλγητικα μεσα
ATE242763T1 (de) Methoximinophenylessigsäureamide
BG103779A (en) Crystallohydrate sodium salt of (e)-4,6-dichloro-3-(2-oxo-1-phenylpyrrolidine-3-ilidenmethyl)-1h-i ndole-2-carboxylic acid
BR0212289A (pt) Anticorpos contra caspase-8, preparação e uso do mesmo
GR1004434B (el) Χρησηατουαdiclofenacαhααποδεκτωνααλατωνααυτουαγιαατηνααντιμετωπισηατωναεγκαυματων
KR960700053A (ko) 방사선회복제로서 리루졸의 이용(application of riluzole as a radiorestorer)
CR6856A (es) Agente terapeutico cristalino

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A, 9A E 10A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2116 DE 26/07/2011.